Pharvaris Advances Oral HAE Therapy with FDA NDA Acceptance
ZUG, Switzerland, July 6, 2026 Pharvaris announced that the U.S. Food and Drug Administration (FDA) has accepted the New...
hereditary angioedema
Advertisement
Argo Biopharma Reports Positive Phase 2 HAE Data for BW-20805
SHANGHAI, China & NEW YORK, USA – June 8, 2026 Argo Biopharma has announced positive updated Phase 2 results...
BioCryst, Neopharmed Sign $345M Europe HAE Deal
RESEARCH TRIANGLE PARK, NORTH CAROLINA, May 04, 2026 BioCryst Pharmaceuticals has announced a strategic European licensing agreement with an...
Intellia Nears Phase 3 CRISPR Data in HAE Breakthrough
Cambridge, Massachusetts | April 24, 2026 Intellia Therapeutics has announced a pivotal milestone in genetic medicine, confirming that it...
KalVista Showcases EKTERLY Data at AAAAI 2026 Meet
FRAMINGHAM, Mass. & SALISBURY, England, Feb. 12, 2026 — KalVista Pharmaceuticals announced the presentation of new clinical and real-world...
Advertisements
WINREVAIR Achieves Phase 2 Success in CpcPH Due to HFpEF
RAHWAY, N.J., Nov. 18, 2025 — Merck (NYSE: MRK) announced positive topline results from the Phase 2 CADENCE study,...
DAWNZERA Wins CHMP Backing for Preventing Hereditary Angioedema Attacks
Carlsbad, California, 14 November 2025 – Ionis Pharmaceuticals, Inc. and Otsuka Pharmaceutical Co., Ltd. announced that the Committee for...
Pharvaris Unveils Breakthrough Oral Therapy for HAE Relief
ZUG, Switzerland, November 10, 2025 — Pharvaris N.V. (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor...
50,000 + Uses of the Syn-One Test® Mark Major Diagnostic Milestone
Scottsdale, AZ — November 6, 2025 : CND Life Sciences (CND) announced the completion of its 50,000th Syn-One Test®,...
KalVista Pharmaceuticals Highlights EKTERLY®’s Promise for Children and Strong Patient Satisfaction in HAE Treatment
Framingham, Massachusetts & Salisbury, England — November 6, 2025 : KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) presented new data at...
Advertisement
